News

Articles

Royalty Pharma is paying $1.6 billion for the royalty rights to Trelegy Ellipta, a treatment for COPD and asthma.

Royalty Pharma Acquires Royalty Rights to COPD/Asthma Treatment for $1.6 Billion

FDA has granted an Emergency Use Authorization to Novavax’s COVID-19 vaccine.

FDA Issues Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted

The Sanofi-GSK vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial with a high-Omicron environment.

First Successful Efficacy Study Against Omicron With COVID-19 Vaccine

Novartis will endorse the Kigali Declaration on neglected tropical diseases and invest $250 million for R&D. 

Novartis to Invest $250 Million for R&D of Neglected Tropical Diseases

GSK will invest £1 billion in furthering R&D in malaria, tuberculosis, and HIV, as well as neglected tropical diseases.

GSK Announces £1 Billion R&D Investment in Fighting Infectious Diseases in Lower-Income Countries

FDA has issued an Emergency Use Authorization for the Moderna and Pfizer-BioNTech COVID-19 vaccines in children as young as six months old.

FDA Authorizes COVID-19 Vaccines for Individuals Six Months and Older

Roche has received approval from the European Commission for Lunsumio (mosunetuzumab), the first CD20xCD3 T-cell engaging bispecific antibody for treating follicular lymphoma.

EC Approves Lunsumio, Roche’s Bispecific Antibody for Follicular Lymphoma

The acquisition grants Bristol Myers Squibb access to the company's oncology pipeline and lead candidate, repotrectinib.

Bristol Myers Squibb Acquires Turning Point Therapeutics for $4.1 Billion

Eli Lilly and Company plans to build two new manufacturing sites at Indiana's LEAP Lebanon Innovation and Research District in Boone County.

Lilly to Invest $2.1 Billion in New Indiana Manufacturing Facilities

GSK’s acquisition of Affinivax will give the company access to their portfolio of next-generation pneumococcal vaccines.

Top News